Basel’s Novartis has been granted EU approval for its tyrosine kinase inhibitor Tasigna for certain pediatric chronic myeloid leukemia (CML) patients. 20 November 2017
A new study conducted at the University of Eastern Finland has found that benzodiazepine and related drug use is associated with a 40% increase in mortality among persons with Alzheimer’s disease. 20 November 2017
The Australian government will invest a record A$24 million (~$18 million) to support landmark research into cardiovascular disease by The George Institute for Global Health. 20 November 2017
New York’s Pfizer has successfully widened the marketable use of oncology drug Sutent to include certain post-surgical renal cell carcinoma patients. 17 November 2017
The US FDA says early results from a safety clinical trial, which it mandated Japanese drugmaker Takeda carry out, show an elevated risk of heart-related death with Uloric (febuxostat), compared to allopurinol. 16 November 2017
Australia Recce Limited, an early stage pharmaceutical company developing a new class of synthetic antibiotics, today announced the US Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) designation for its lead compound RECCE 327. 16 November 2017
GlaxoSmithKline and Innoviva have been granted marketing authorization in the EU for Trelegy Ellipta as a maintenance treatment for chronic obstructive pulmonary disease. 16 November 2017
Drug development services organization Quotient Sciences says it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, UK. 14 November 2017
The Food and Drug Administration granted regular approval for Sprycel (dasatinib) from Bristol-Myers Squibb for the treatment of pediatric patients with Philadelphia chromosome 13 November 2017
The Food and Drug Administration has approved the supplemental New Drug Application (sNDA) submitted by Ireland-incorporated Allergan for Vraylar (cariprazine) for the maintenance treatment of adults with schizophrenia. 13 November 2017
A trade group representing pharma in Europe has reiterated its stance in relation to the post-Brexit relocation of the European Medicines Agency (EMA). 13 November 2017
UK-based rare and specialty diseases specialist Mereo BioPharma has had its drug for osteogenesis imperfecta (OI), or brittle bone disease, granted PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA). 13 November 2017
Uruguay’s Grupo Biotoscana has acquired Laboratorio DOSA, a specialty pharmaceutical manufacturer based in Argentina, for around $30 million. 13 November 2017
Novartis has presented new results from a real-world database study of patients in Germany prescribed Entresto (sacubitril/valsartan) for heart failure with reduced ejection fraction. 13 November 2017
The Institute for Clinical and Economic Review (ICER), the highly-referenced Boston, USA-based research institute, has announced it plans to conduct a formal review of erenumab. 10 November 2017
French pharma major Ipsen has announced the appointment of Alexis Vandier as general manager of the company’s France operation, effective 31 October. 10 November 2017
A study comparing the efficacy of opioids with non-opioid alternatives in an emergency room setting has found no difference in pain reduction after two hours with ibuprofen and acetaminophen versus three comparison opioid-acetaminophen combinations. 9 November 2017
New Zealand’s Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with Merck Sharpe & Dohme Limited, the local subsidiary of US pharma giant Merck & Co, to fund the zoster vaccine Zostavax for the prevention of shingles (herpes zoster) from April 1, 2018. 9 November 2017
Europe’s umbrella group for pharma trade bodies, EFPIA, says a new survey underlines “the sheer scale and importance of the medicines issues that must be addressed” as part of Brexit discussions. 9 November 2017
London-based GlaxoSmithKline has announced results from a study of lupus patients treated with Benlysta plus standard of care (SoC) versus SoC alone. 9 November 2017
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024